Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ablynx NV - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Ablynx NV - Product Pipeline Review - 2015', provides an overview of the Ablynx NV's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Ablynx NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Ablynx NV including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Ablynx NV's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Ablynx NV's pipeline products Reason To Buy - Evaluate Ablynx NV's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Ablynx NV in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Ablynx NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Ablynx NV and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ablynx NV - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Ablynx NV and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Ablynx NV Snapshot 6 Ablynx NV Overview 6 Key Information 6 Key Facts 6 Ablynx NV - Research and Development Overview 7 Key Therapeutic Areas 7 Ablynx NV - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 Ablynx NV - Pipeline Products Glance 16 Ablynx NV - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Ablynx NV - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Ablynx NV - Drug Profiles 20 ALX-0061 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ALX-0171 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 caplacizumab 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ozoralizumab 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ALX-0141 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Monoclonal Antibody to Target c-Met for Multiple Myeloma 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 TLC-520 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Monoclonal Antibodies for Inflammation, Immunology and Infections 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Monoclonal Antibodies for Oncology, Immunology and Neurology 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Monoclonal Antibody 1 for Inflammation and Immunology 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Monoclonal Antibody 1 for Oncology 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Monoclonal Antibody 1 for Pulmonary Disease 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Monoclonal Antibody 2 for Inflammation and Immunology 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Monoclonal Antibody 2 for Oncology 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Monoclonal Antibody 2 for Pulmonary Disease 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Monoclonal Antibody 3 for Inflammation and Immunology 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Monoclonal Antibody for Immunology 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Monoclonal Antibody for Ocular Diseases 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Monoclonal Antibody for Pulmonary Diseases 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Ablynx NV - Pipeline Analysis 44 Ablynx NV - Pipeline Products by Target 44 Ablynx NV - Pipeline Products by Route of Administration 45 Ablynx NV - Pipeline Products by Molecule Type 46 Ablynx NV - Pipeline Products by Mechanism of Action 47 Ablynx NV - Recent Pipeline Updates 48 Ablynx NV - Dormant Projects 56 Ablynx NV - Dormant Projects 56 Ablynx NV - Discontinued Pipeline Products 57 Discontinued Pipeline Product Profiles 57 ALX-0962 57 BI-1034020 57 Ablynx NV - Company Statement 58 Ablynx NV - Locations And Subsidiaries 61 Head Office 61 Other Locations & Subsidiaries 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Ablynx NV, Key Information 6 Ablynx NV, Key Facts 6 Ablynx NV - Pipeline by Indication, 2015 8 Ablynx NV - Pipeline by Stage of Development, 2015 10 Ablynx NV - Monotherapy Products in Pipeline, 2015 11 Ablynx NV - Partnered Products in Pipeline, 2015 12 Ablynx NV - Partnered Products/ Combination Treatment Modalities, 2015 13 Ablynx NV - Out-Licensed Products in Pipeline, 2015 14 Ablynx NV - Out-Licensed Products/ Combination Treatment Modalities, 2015 15 Ablynx NV - Phase II, 2015 16 Ablynx NV - Phase I, 2015 17 Ablynx NV - Preclinical, 2015 18 Ablynx NV - Discovery, 2015 19 Ablynx NV - Pipeline by Target, 2015 44 Ablynx NV - Pipeline by Route of Administration, 2015 45 Ablynx NV - Pipeline by Molecule Type, 2015 46 Ablynx NV - Pipeline Products by Mechanism of Action, 2015 47 Ablynx NV - Recent Pipeline Updates, 2015 48 Ablynx NV - Dormant Developmental Projects,2015 56 Ablynx NV - Discontinued Pipeline Products, 2015 57 Ablynx NV, Subsidiaries 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.